Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668414 · ClinicalTrials.gov registry record · Phase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
NCT07668414 is a Phase 3 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 650 participants.
The verdict
NCT07668414, a Phase 3 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Interventions
- DRUG Semaglutide
- DRUG Zenagamtide
- DRUG Placebo (matched to semaglutide)
- DRUG Placebo (matched to zenagamtide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2026-09-22 |
| Est. Completion | 2028-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07668414
The ClinicalTrials.gov registry entry for NCT07668414 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT07668414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07668414 about?
NCT07668414 is a clinical study titled "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide". The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
What is the current status of trial NCT07668414?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2026-09-22. Estimated completion is 2028-10-10.
What interventions are being tested in trial NCT07668414?
The interventions under investigation include: Semaglutide (DRUG), Zenagamtide (DRUG), Placebo (matched to semaglutide) (DRUG), Placebo (matched to zenagamtide) (DRUG).
Who is sponsoring clinical trial NCT07668414?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.